Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers

This research study is evaluating a new method for determining stage and prognosis of individuals with malignant pleural mesothelioma.

Primary Outcome Measures

  • Pre-treatment Prognostic Algorithm Validation [ Time Frame: 4 years ]
    The primary outcome will be to prospectively validate a pre-treatment prognostic algorithm to predict survival for MPM patients.

Secondary Outcome Measures

    • Evaluation of Molecular Tests Base on RNA Expression [ Time Frame: 4 years ]
      A secondary outcome will be to evaluate molecular tests that are based on RNA expression. Specimens will be collected to develop and test new prognostic and predictive signatures for MPM based on consensus cluster membership and other potential biomarkers.
Inclusion Criteria
  • All adult patients with a diagnosis of malignant pleural mesothelioma undergoing
    • diagnostic pleural biopsy
    • pleuroscopy
    • and/or VATS resections
  • Participants must be 18 years of age or older.

 

Exclusion Criteria:
Any patient who is found to be unsuitable for

« Mesothelioma Clinical Trials Main Page.

Source: the U.S. National Institutes of Health via ClinicalTrials.gov. Last updated: October 12th, 2018.

You can follow any responses to this entry through the RSS 2.0 feed.

Both comments and pings are currently closed.

Comments are closed.

Last update: January 19, 2018. 04:57:31 pm.